(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\nNEWS AKTUELL \/\/ Teltow, Germany, 05. February 2025 \u2013 The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.<\/p>\n
\nm2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.<\/p>\n
\u00abWe are proud to be a partner in the m2M project and believe in its potential to significantly advance the development of therapies for the regeneration of tissue. We are happy to contribute and share our more than 30 years of experience in the field of regenerative medicine as well as our regulatory expertise as the holder of an EU approved cell-based therapy for cartilage repair\u00bb explained Dr. Giulietta Ro\u00ebl, Executive Director of CO.DON GmbH.<\/p>\n
\nBeyond technical development, m2M will foster knowledge exchange and workshops to enhance researchers’ and healthcare professionals’ skills across Europe.<\/p>\n
\n\u2022 LinkedIn page of the research project<\/p>\n
\n\u2022 More information about the research project and its funding<\/p>\n
\nCO.DON develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient’s own cartilage cells. More than 20,000 patients have already been treated with CO.DON’s method. In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies, a global company headquartered in the US.<\/p>\n
\nManaging Director: Dr. Ying Zhou<\/p>\n
\nFurther information is available at www.codon.de<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) NEWS AKTUELL \/\/ Teltow, Germany, 05. February 2025 \u2013 The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-59077","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/59077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59077"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/59077\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}